

Publications of the International Breast Cancer Study Group

IBCSG 13-93

126. Kitchen PRB, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. *ANZ J Surg* 71:27-31, 2001. (Trials I-14)
146. Sabbioni MEE, Bernhard J, Siegrist H-P, Schmitz S-FH, Castiglione-Gertsch M, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C for the SAKK. Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? *Breast Cancer Research and Treatment* 87: 75-86, 2004. (VI, VII, VIII, IX, 13-93, 14-93)
168. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93. *J Clin Oncol* 24:1332-1341, 2006. (Journal impact factor 9.8)
180. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS & Goldhirsch A for the IBCSG. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. *Ann Oncol* 18:701-708, 2007. (Trials VIII, IX, 11-15) (Journal impact factor 4.3)
188. International Breast Cancer Study Group. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) trials 13-93 and 14-93. *Ann Oncol* 18:1177-1184, 2007. (Journal impact factor 5.2).
198. Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni M, Aebi S, Simoncini E, Pagani O, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, Ravaioli A. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. *Support Care Cancer* 16:67-74, 2008. (Trials 13-14) (Journal impact factor 1.9).
209. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol* 26:3006-3014, 2008. (Trials I-15) (Journal impact factor 13.6).